RBM47 as a Target for Glioma Treatment
Author Information
Author(s): Wei Wei, Cao Yongfu, Lu Xin, Wang Long, Li Jianbin, Deng Guojun, Li Donghai, Xiao Limin
Primary Institution: The First Affiliated Hospital, Jiangxi Medical College, Nanchang University
Hypothesis
The study investigates the role of RBM47 in gliomas and its potential as an immunotherapeutic target.
Conclusion
RBM47 is highly expressed in gliomas and is associated with poor prognosis, suggesting it may serve as a prognostic biomarker and immunotherapy target.
Supporting Evidence
- RBM47 expression is higher in gliomas than in normal tissues.
- Increased RBM47 expression correlates with higher WHO tumor grades.
- RBM47 serves as an independent predictor of overall survival.
- The nomogram combining RBM47 with clinical factors has a C-index of 0.863.
- RBM47 is associated with immune functions and inflammatory responses.
- RBM47 is enriched in M2 macrophages within the glioma microenvironment.
- High RBM47 expression predicts poorer survival outcomes in glioma patients.
- RBM47 may be a candidate for combination therapy with immune checkpoint inhibitors.
Takeaway
RBM47 is a protein that helps glioma tumors grow and can be used to predict how well patients will do. It might also be a good target for new treatments.
Methodology
The study used multi-omic datasets, bioinformatics analyses, and clinical data to investigate RBM47's role in gliomas, validated by immunohistochemistry and immunofluorescence.
Limitations
The study included limited in vitro experimental validation and requires more comprehensive in vivo validation.
Participant Demographics
{"gender":{"male":354,"female":255},"WHO_grade":{"grade_II":216,"grade_III":241,"grade_IV":152}}
Statistical Information
P-Value
1.5E-73
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website